Department of Endocrinology and Metabolism, the Second Affiliated Hospital of Nanchang University, Nanchang, China; Institute for the Study of Endocrinology and Metabolism in Jiangxi Province, Nanchang, China; Branch of National Clinical Research Center for Metabolic Diseases, Nanchang, China.
Department of Endocrinology and Metabolism, the Second Affiliated Hospital of Nanchang University, Nanchang, China; Institute for the Study of Endocrinology and Metabolism in Jiangxi Province, Nanchang, China; Branch of National Clinical Research Center for Metabolic Diseases, Nanchang, China.
Endocr Pract. 2023 May;29(5):368-378. doi: 10.1016/j.eprac.2023.02.004. Epub 2023 Feb 17.
Wearable activity monitors are promising tools for improving metabolic outcomes in patients with type 2 diabetes mellitus (T2DM); however, no uniform conclusive evidence is available. This study aimed to evaluate the effects of the intervention using wearable activity monitors on blood glucose, blood pressure, blood lipid, weight, waist circumference, and body mass index (BMI) in individuals with T2DM.
Two independent reviewers searched 4 online databases (PubMed, Cochrane Library, Web of Science, and Embase) to identify relevant studies published from January 2000 to October 2022. The primary outcome indicator was hemoglobin A1c (HbA1c), and the secondary outcome indicators included physical activity (steps per day), fasting blood glucose, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, systolic blood pressure, diastolic blood pressure, BMI, waist circumference, and weight.
A total of 25 studies were included. The HbA1c level (standardized mean difference [SMD], -0.14; 95% confidence interval [CI], -0.27 to -0.02; P = .02; I = 48%), BMI (SMD, -0.16; 95% CI, -0.26 to -0.05; P = .002; I = 0), waist circumference (SMD, -0.21; 95% CI, -0.34 to -0.09; P < .001; I = 0), and steps/day (SMD, 0.55; 95% CI, 0.36-0.94; P < .001; I = 77%) significantly improved.
Wearable activity monitor-based interventions could facilitate the improvement of the HbA1c level, BMI, and waist circumference and increase in physical activity in individuals with T2DM. Wearable technology appeared to be an effective tool for the self-management of T2DM; however, there is insufficient evidence about its long-term effect.
可穿戴活动监测器是改善 2 型糖尿病（T2DM）患者代谢结局的有前途的工具，但目前尚无明确的结论性证据。本研究旨在评估使用可穿戴活动监测器对 T2DM 患者血糖、血压、血脂、体重、腰围和体重指数（BMI）的干预效果。
两名独立评审员检索了 4 个在线数据库（PubMed、Cochrane Library、Web of Science 和 Embase），以确定从 2000 年 1 月至 2022 年 10 月发表的相关研究。主要结局指标为糖化血红蛋白（HbA1c），次要结局指标包括身体活动（每日步数）、空腹血糖、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、总胆固醇、收缩压、舒张压、BMI、腰围和体重。
共纳入 25 项研究。HbA1c 水平（标准化均数差 [SMD]，-0.14；95%置信区间 [CI]，-0.27 至-0.02；P =.02；I² = 48%）、BMI（SMD，-0.16；95%CI，-0.26 至-0.05；P =.002；I² = 0）、腰围（SMD，-0.21；95%CI，-0.34 至-0.09；P <.001；I² = 0）和每日步数（SMD，0.55；95%CI，0.36-0.94；P <.001；I² = 77%）均显著改善。
基于可穿戴活动监测器的干预措施可促进 T2DM 患者 HbA1c 水平、BMI 和腰围的改善，并增加身体活动。可穿戴技术似乎是 T2DM 自我管理的有效工具，但关于其长期效果的证据不足。
